Improved Survival and Response With Lenvatinib ± Everolimus vs Everolimus Alone in Metastatic RCC

May 29-June 2, 2015; Chicago, Illinois
Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 540 KB
Released: June 4, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Download this free slideset by Elizabeth R. Plimack, MD, MS, for a summary of clinical data on the use of immune checkpoint inhibitor-based therapy for patients with metastatic urothelial carcinoma.

Elizabeth R. Plimack, MD, MS Released: November 7, 2019

Download this slideset by Matthew Galsky, MD, to see recent data and ongoing clinical trials with immune checkpoint inhibitors for patients with muscle-invasive bladder cancer.

Matthew Galsky, MD Released: November 7, 2019

Review key clinical data in prostate cancer and urothelial carcinoma from ASCO 2019 with this expert analysis from Daniel P. Petrylak, MD

Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 16, 2019 Expiration: August 15, 2020

A CME-certified activity with insights on the optimal care of advanced gastric/GEJ cancers using checkpoint inhibitors from Clinical Care Options

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Axel Grothey Headshot Axel Grothey, MD Steven Maron, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: August 9, 2019 Expiration: August 8, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?